ROCKLATAN/ROCLANDA Strengthens Market Position with Robust Sales and Patient Outcomes | DelveInsight
ROCKLATAN/ROCLANDA (netarsudil and latanoprost ophthalmic solution) 0.02% and 0.005% is a prescription drug used to lower ...
The Xalatan Ophthalmic Solution, 0.005% market achieved annual sales of approximately $113.5 million, according to IQVIA sales data for the 12-month period that ended in December 2024. The ...
Drug-loaded contact lenses for glaucoma treatment appear to demonstrate safety and effectiveness in reducing IOP, according to a systematic review published in European Journal of Pharmacology. Drug-l ...
Purpose: We investigated the intraocular pressure (IOP) variations after switching from 0.005% latanoprost to 0.01% bimatoprost in open-angle glaucoma patients who experienced IOP elevation during ...
(RTTNews) - Glenmark Pharmaceuticals Ltd. (GLENMARK.NS), Friday announced that it has introduced Latanoprost Ophthalmic Solution, 0.005 percent, a bioequivalent and therapeutically equivalent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback